These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 23806811)

  • 21. Interaction of omeprazole with enteric-coated salicylate tablets.
    Nefesoglu FZ; Ayanoglu-Dülger G; Ulusoy NB; Imeryüz N
    Int J Clin Pharmacol Ther; 1998 Oct; 36(10):549-53. PubMed ID: 9799060
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enantioselective disposition of omeprazole, pantoprazole, and lansoprazole in a same Brazilian subjects group.
    Cassiano NM; Oliveira RV; Bernasconi GC; Cass QB
    Chirality; 2012 Apr; 24(4):289-93. PubMed ID: 22344845
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetic studies in healthy volunteers on a new gastroprotective pharmaceutic form of diclofenac.
    De Bernardi di Valserra M; Feletti F; Tripodi AS; Contos S; Carabelli A; Maggi L; Germogli R
    Arzneimittelforschung; 1993 Mar; 43(3):373-7. PubMed ID: 8489569
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Controlled release floating drug delivery system for proton pump inhibitors lansoprazole: In-vitro, In-vivo floating and pharmacokinetic evaluation.
    Murad S; Mudassir J; Faiz S; Zahra A; Usman F; Farhan M; Arshad MS; Abbas N; Hussain A; Faran Ashraf Baig MM
    Pak J Pharm Sci; 2022 Jan; 35(1(Supplementary)):195-201. PubMed ID: 35228177
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Delayed release film coating applications on oral solid dosage forms of proton pump inhibitors: case studies.
    Missaghi S; Young C; Fegely K; Rajabi-Siahboomi AR
    Drug Dev Ind Pharm; 2010 Feb; 36(2):180-9. PubMed ID: 20070183
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Formulation study for lansoprazole fast-disintegrating tablet. I. Effect of compression on dissolution behavior.
    Shimizu T; Nakano Y; Morimoto S; Tabata T; Hamaguchi N; Igari Y
    Chem Pharm Bull (Tokyo); 2003 Aug; 51(8):942-7. PubMed ID: 12913232
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative bioavailability and pharmacokinetics of investigational enteric- and film-coated formulations of flurbiprofen 100-mg tablets: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy Pakistani male volunteers.
    Ahmad M; Pervaiz F
    Clin Ther; 2010 Mar; 32(3):607-13. PubMed ID: 20399997
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dissolution modeling of bead formulations and predictions of bioequivalence for a highly soluble, highly permeable drug.
    Sperry DC; Thomas SJ; Lobo E
    Mol Pharm; 2010 Oct; 7(5):1450-7. PubMed ID: 20704266
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design and evaluation of enteric-coated tablets for rifampicin and isoniazid combinations.
    Wang Y; Liu H; Liu K; Sun J; He Z
    Pharm Dev Technol; 2013; 18(2):401-6. PubMed ID: 22339279
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combining biorelevant in vitro and in silico tools to simulate and better understand the in vivo performance of a nano-sized formulation of aprepitant in the fasted and fed states.
    Litou C; Patel N; Turner DB; Kostewicz E; Kuentz M; Box KJ; Dressman J
    Eur J Pharm Sci; 2019 Oct; 138():105031. PubMed ID: 31386891
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Leaky enteric coating on ranitidine hydrochloride beads: dissolution and prediction of plasma data.
    Bendas ER; Ayres JW
    Eur J Pharm Biopharm; 2008 Aug; 69(3):977-85. PubMed ID: 18424095
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Investigation of the relationship between in vitro and in vivo release behaviors of acamprosate from enteric-coated tablets.
    Rhee YS; Park S; Lee TW; Park CW; Nam TY; Oh TO; Jeon JW; Lee DS; Park ES
    Arch Pharm Res; 2008 Jun; 31(6):798-804. PubMed ID: 18563364
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intragastric acidity and omeprazole exposure during dosing with either PA32540 (enteric-coated aspirin 325 mg + immediate-release omeprazole 40 mg) or enteric-coated aspirin 325 mg + enteric-coated omeprazole 40 mg - a randomised, phase 1, crossover study.
    Miner PB; Fort JG; Zhang Y
    Aliment Pharmacol Ther; 2013 Jul; 38(1):62-71. PubMed ID: 23692061
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bioequivalence of two enteric coated formulations of pantoprazole in healthy volunteers under fasting and fed conditions.
    de Campos DR; Vieira NR; Bernasconi G; Barros FA; Meurer EC; Marchioretto MA; Coelho EC; Calafatti SA; Sommer C; Couto JM; Buranello S; Silva AR; Amarante AR; Abib E; Júnior JP
    Arzneimittelforschung; 2007; 57(6):309-14. PubMed ID: 17688075
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of Gastric H
    Phutthatiraphap S; Hayashi Y; Fujii T; Kosugi A; Okada K; Kadozaki T; Ishise T; Sakai H; Onuki Y
    Chem Pharm Bull (Tokyo); 2018; 66(9):896-900. PubMed ID: 30175749
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A novel option for dosing of proton pump inhibitors: dispersion of lansoprazole orally disintegrating tablet in water via oral syringe.
    Gremse DA; Donnelly JR; Kukulka MJ; Lloyd E; Lee C
    Aliment Pharmacol Ther; 2004 Jun; 19(11):1211-5. PubMed ID: 15153174
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The biowaiver extension for BCS class III drugs: the effect of dissolution rate on the bioequivalence of BCS class III immediate-release drugs predicted by computer simulation.
    Tsume Y; Amidon GL
    Mol Pharm; 2010 Aug; 7(4):1235-43. PubMed ID: 20557130
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prediction of the in vivo performance of enteric coated pellets in the fasted state under selected biorelevant dissolution conditions.
    Stefanič M; Vrečer F; Rizmal P; Mrhar A; Bogataj M
    Eur J Pharm Sci; 2014 Oct; 62():8-15. PubMed ID: 24844699
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mechanistic investigation of food effect on disintegration and dissolution of BCS class III compound solid formulations: the importance of viscosity.
    Radwan A; Amidon GL; Langguth P
    Biopharm Drug Dispos; 2012 Oct; 33(7):403-16. PubMed ID: 22782559
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mechanism-based prediction of particle size-dependent dissolution and absorption: cilostazol pharmacokinetics in dogs.
    Willmann S; Thelen K; Becker C; Dressman JB; Lippert J
    Eur J Pharm Biopharm; 2010 Sep; 76(1):83-94. PubMed ID: 20554023
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.